|
Cutaneous Melanoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Cutaneous malignant melanoma is the leading cause of death from skin diseases and is often associated with activating mutations of the proto-oncogene BRAF.
|
25174976 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations have recently been detected with a high frequency (66%) in cutaneous melanoma.
|
14501284 |
2003 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site.
|
21324100 |
2011 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) is the most common mutation in cutaneous melanoma and has become the target of treatment for patients with metastatic melanoma.
|
23211290 |
2013 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation is seen in a variety of human neoplasms including cutaneous malignant melanoma, papillary thyroid carcinoma, colorectal carcinoma, non-small cell lung carcinoma, pleomorphic xanthoastrocytoma, and others.
|
24071017 |
2013 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations are present in 40% of human skin melanomas.
|
26141748 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma.
|
27145091 |
2016 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRAF inhibitors substantially have impressive clinical efficacy in cutaneous melanoma.
|
28485171 |
2019 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRAF and MEK inhibitors have demonstrated significant survival benefits for patients with cutaneous melanoma.
|
30205280 |
2018 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF is the most frequently mutated gene in skin melanoma.
|
30347273 |
2018 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF inhibitors target the BRAF-V600E/K mutated kinase, the driver mutation found in 50% of cutaneous melanoma.
|
30429474 |
2018 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A set of 250 probes representing 209 genes that were significantly (raw P< or =0.001) associated with BRAF mutation status was identified and 17 of these were previously shown to be implicated in cutaneous melanoma progression or pigmentation pathway-associated genes driven by the microphthalmia transcription factor (MITF).
|
19383316 |
2008 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A total of 46 adult lymph node-positive primary skin melanoma patients (23 BRAF-mutant and 23 BRAF-wild) with available information on the mutational status of the oncogene BRAF V600E were included in the analysis.
|
30997532 |
2019 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Absence of BRAF gene mutation in non-melanoma skin tumors.
|
16687919 |
2006 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapy regimens for the treatment of advanced BRAF-mutant melanoma, though the rate of BRAF mutation gene-bearing cutaneous melanoma is limited, especially in the Asian population.
|
31514399 |
2019 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Additionally, an analysis of the correlation network reconstructed using TCGA-SKCM emphasized KMO and KYNU with high variability among BRAF wild-type compared with V600E, which underscored their role in distinct CD4+ T-cell behavior in tumour immunity.
|
31434983 |
2019 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Among 41 response-evaluable patients, 2 (5 %) patients with cutaneous melanoma (one with BRAF L597R mutant melanoma) had partial responses.
|
27650277 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
An activating mutation has been recently observed in cutaneous melanoma in a downstream component of RAS-BRAF.
|
15179189 |
2004 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma.
|
26848795 |
2016 |
|
Cutaneous Melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Archived consecutive samples (n=107) of primary cutaneous melanoma were retrieved and assessed for the following: CXCR4 mRNA (semiquantitative RT-PCR) and BRAF exon 15 status (DNA Sanger sequencing).
|
25211166 |
2014 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
As the current knowledge about pathogenesis, clinical and genetic features of cutaneous melanoma is not very clear, we aim to use bioinformatics to identify the potential key genes involved in the expression and mutation status of BRAF.
|
30925905 |
2019 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Association between dermoscopic and reflectance confocal microscopy features of cutaneous melanoma with BRAF mutational status.
|
27790766 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Because the Mitogen-Activated Protein Kinase (MAPK) pathway plays such a significant role in melanoma development, we explore v-raf murine sarcoma viral oncogene homolog B (<i>BRAF)</i> and neuroblastoma RAS viral oncogene homolog (<i>NRAS)</i> mutations in mucosal melanoma and compare them to the mutation profiles in cutaneous melanoma and other tumors with <i>BRAF</i> and <i>NRAS</i> mutations.
|
31398831 |
2019 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
|
26055532 |
2015 |